Increlex (Mecasermin)

Increlex (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Limitations of use: Increlex is not a substitute for GH for approved GH indications. It is not indicated for use in patients with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of antiinflammatory corticosteroids.

Recommended Dosage: 

The recommended starting dose of Increlex is 0.04 mg/kg to 0.08 mg/kg of body weight twice daily by subcutaneous (upper arm, thigh, buttock, or abdomen) injection. Do not administer it intravenously. If well-tolerated for at least one week, the dose may be increased by 0.04 mg/kg of body weight per dose, to the maximum dose of 0.12 mg/kg of body weight given twice daily. 

Before starting treatment, blood sugar should be checked before meals until the correct and comfortable dose is found. If the patient often feels symptoms of low blood sugar or has a severe episode, pre-meal monitoring should continue, and sugar levels should be checked during the episode if possible. If low blood sugar happens despite proper meals, the dose should be lowered. Increlex should be administered shortly before or after (± 20 minutes) a meal or snack. If the patient is not able to eat shortly before or after a dose for any reason, that dose should be withheld.

If one or more doses of Increlex are missed, do not increase the subsequent doses to make up for omitted doses.

• Treatment with Increlex 40 mg/4 mL (10 mg/mL) can cause serious low blood sugar, which may lead to seizures. It should be given within 20 minutes before or after a meal or snack. Monitor blood sugar levels regularly. Extra care is required for young children with inconsistent eating habits.
• Serious allergic reactions may occur, including itching, swelling, difficulty breathing, rash, or anaphylaxis. Patients must seek immediate medical assistance in case symptoms occur. Stop treatment if a life-threatening allergic reaction is noted and evaluate before considering further administration.
• Increased pressure inside the skull may occur in some patients. Signs include nausea, severe headache, vision changes, or vomiting. Regular eye examinations are required during treatment. In case symptoms occur, medical evaluation is important and temporary discontinuation may be needed.
• Enlargement of lymphoid tissues, such as tonsils and adenoids, may occur during treatment. This may cause breathing difficulties, snoring, sleep apnea, or ear complications. Monitor patients for airway obstruction symptoms and consider medical assessment in case persistent or serious complications develop.
• Quick growth may increase the risk of hip complications such as slipped capital femoral epiphysis. Patients may experience hip, thigh, or knee pain and difficulty walking. Prompt evaluation is needed if these symptoms occur to prevent further joint damage.
• Growth acceleration may worsen existing spinal curvature in patients with scoliosis. Monitor patients regularly for changes in posture or back alignment. Early detection and orthopedic assessment are important to manage progression and reduce potential long-term complications.
• Increlex 40 mg/4 mL (10 mg/mL) injection should not be used in patients with active or suspected cancer. There is a potential risk of tumor growth stimulation. Patients with a history of malignancy require careful evaluation before treatment and regular monitoring throughout therapy.
• There is limited information regarding use during pregnancy. Treatment should only be used if clearly initiated and after evaluating potential risks and benefits. Women who are pregnant or planning pregnancy should discuss treatment continuation with their clinician.
  It is not known whether this medicine passes into human breast milk. Caution is required when administering to breastfeeding women. Clinicians should assess the potential benefits of treatment against possible risks to the nursing infant before continuing therapy.

What documents are required to import INCRELEX to India?

INCRELEX (mecasermin) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is INCRELEX available in India?

INCRELEX (mecasermin injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Increlex in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Increlex price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

INCRELEX can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of INCRELEX (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91 98104 69557 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Increlex cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source INCRELEX (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Increlex®?

Mecasermin is the Generic Name for the trade name drug Increlex®.

What is the Manufacturer’s Name of Increlex®?

Increlex® is manufactured by Eton Pharmaceuticals.

Is Increlex approved by the FDA?

Yes. Increlex is approved by the FDA. Date of first approval: August 30, 2005.

What is the dosage and form of Increlex® supplied?

Increlex is supplied as an injection: 40 mg/4 mL (10 mg/mL) solution supplied in a multiple-dose glass vial for subcutaneous use.

What are the most common side effects of Increlex® 40 mg/4 mL (10 mg/mL) Injections? 

The most commonly reported side effects of Increlex® are hypoglycemia, local and systemic hypersensitivity, and tonsillar hypertrophy.

How does Increlex Import in India work?

Increlex Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How much does Increlex® 40 mg/4 mL (10 mg/mL) injection cost in India?

Increlex® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Increlex prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Increlex cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Increlex® 40 mg/4 mL (10 mg/mL) injection be available in SAARC countries? 

Apart from Gulf countries, Increlex® 40 mg/4 mL (10 mg/mL) can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Increlex® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Increlex® 40 mg/4 mL (10 mg/mL) Injections online in India?

Yes, one can buy Increlex in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Increlex® injection through legal channels. 

What are the storage conditions of Increlex® 40 mg/4 mL (10 mg/mL) Injections?

Store the vials in a refrigerator between 2°C and 8°C. Do not freeze and keep away from direct light. After opening, store refrigerated and use within 30 days. Discard any unused medicine after 30 days.